From University Innovation to Retail-Ready Products: Maravion Supporting SMMEs in High-Value Cosmetic Manufacturing

South Africa has a significant opportunity to build a stronger, more inclusive cosmetics and personal care manufacturing sector. The country combines established scientific and research capabilities, a sophisticated retail environment, entrepreneurial SMMEs and a growing interest in locally developed products.

But turning these ingredients into sustainable businesses requires more than a good idea.

For small cosmetic enterprises, the difficult part is often the journey from an initial concept or home-developed product to a professionally formulated, tested, branded and commercially manufactured product that can compete for space on a retail shelf.

At Maravion, we have been working with the University of the Western Cape (UWC) and five South African SMMEs to address precisely this challenge.

The programme supports five SMMEs in developing four products each around a proprietary UWC-developed ingredient, Cotisyl, based on silver nanoparticles and botanical components. The objective is ambitious but practical: to take university-developed intellectual property and place it in the hands of entrepreneurs who can transform it into differentiated, commercial products.

In total, the programme has the potential to create 20 new cosmetic and personal care products, while simultaneously developing the capabilities of the participating enterprises.

1              Bridging the Gap Between University IP and the Market

Universities generate considerable scientific knowledge and intellectual property. However, the existence of a promising technology does not automatically create a product, a business or an economic impact.

There is an extensive commercialisation journey between the laboratory and the retail shelf.

UWC's technology provided the scientific foundation for the programme. The underlying concept combines silver nanoparticle technology with botanical components, with antibacterial activity forming an important element of the technology's value proposition.

The original technology prospectus identified several possible product applications, including bar soap, hand wash, body wash and face wash. It also positioned the technology as an opportunity for established cosmetic entrepreneurs, with particular emphasis on SMEs and black- and female-owned businesses.

Maravion's role has been to help bridge the commercialisation gap between this technology platform and products that entrepreneurs can actually manufacture, brand and take to market.

2              Five SMMEs. Four Products Each. One Commercialisation Journey.

Rather than simply transferring an ingredient or formulation to the participating businesses, the programme was designed around the entire product development value chain.

Each SMME is being supported to develop four products, creating a portfolio rather than a single experimental product.

The process takes the entrepreneurs through the stages required to transform an innovation into a commercial proposition:

Idea and product concept → Formulation → Product optimisation → Antibacterial testing → Skin safety testing → Stability and shelf-life assessment → Branding and graphic design → Trade marks → Contract manufacturing → Market-ready product

This end-to-end approach is important.

Many SMMEs can formulate interesting products. Far fewer have the technical resources, networks or capital required to independently navigate specialist testing, product optimisation, intellectual property, manufacturing and market preparation.

Commercialisation support therefore needs to address the whole value chain rather than isolated interventions.

3              Starting with the Consumer and the Product

Technology commercialisation should not begin with the assumption that a technology will automatically find a market.

The first challenge is translating the technical characteristics of an ingredient into a product proposition that consumers will understand and value.

For the participating SMMEs, this meant exploring how the Cotisyl technology could be incorporated into products aligned with their existing brands, customers and market positioning.

The programme therefore began with ideation and product selection before moving into formulation development.

This allows each entrepreneur to create products with their own brand identity while leveraging a common university-developed technology platform.

4              Formulation Is Only the Beginning

A formulation that looks, smells and feels good is not necessarily commercially ready.

The formulation must remain stable. Ingredients must remain compatible. The product needs an appropriate shelf life. Claims need supporting evidence. And, critically, products intended for repeated use on the skin need an appropriate safety assessment.

Maravion therefore coordinated the technical development and testing pathway required to move the products progressively towards commercial readiness.

This included formulation development and optimisation, antibacterial testing, skin patch and dermatological testing, and shelf-life or stability testing.

Because antibacterial performance is central to the Cotisyl proposition, substantiation of this functionality is particularly important.

The original UWC technology had already demonstrated strong antibacterial performance during testing at a SANAS-accredited laboratory, providing an important scientific foundation for subsequent product development.

However, translating an ingredient into different finished formulations requires careful consideration of the final products themselves. Commercialisation cannot rely solely on the performance of the underlying technology.

5              From Scientific Claim to Consumer Confidence

This distinction is fundamental to science-based cosmetic innovation.

Consumers increasingly encounter products making claims around natural ingredients, antimicrobial properties, skin health and advanced technologies. For responsible manufacturers, these claims should be supported by appropriate evidence.

For an SMME, accessing the necessary laboratories, understanding what testing is required and managing the testing process can represent a significant barrier to market entry.

By coordinating these activities across five enterprises, the programme enables the SMMEs to access capabilities that would be considerably more difficult to establish individually.

It is an example of how shared commercialisation infrastructure can reduce barriers for smaller manufacturers.

6              A Product Is More Than Its Formulation

Technical validation alone does not create a retail product.

Consumers encounter the brand, packaging and label long before they encounter the science behind the formulation.

The programme therefore extends beyond laboratory development into the commercial identity of each product.

Participating businesses are supported with label development, graphic design and trade mark considerations, helping them transform formulations into recognisable branded products suitable for commercial presentation.

This stage is sometimes underestimated in technology commercialisation.

The transition from a laboratory sample in a generic container to a professionally packaged product carrying a distinctive brand represents a major psychological and commercial milestone for an entrepreneur.

It signals the transition from "something we developed" to "something we can sell".

7              Taking SMMEs into High-Value Manufacturing

There is also a broader economic development objective behind the programme.

South Africa is already Africa's largest cosmetics and personal care market and has established R&D capabilities and an extensive retail network. Government investment information also identifies opportunities for increased local manufacturing, particularly given the country's continued dependence on imported cosmetic raw materials.

The opportunity is therefore not simply to create more small cosmetic brands.

It is to help South African SMMEs move progressively into higher-value activities involving technology, intellectual property, validated formulations, quality-controlled manufacturing and differentiated products.

That distinction matters.

An entrepreneur who purchases generic products and resells them participates in the cosmetics economy. An entrepreneur who owns a brand, understands formulation, works with proprietary technology, manages quality and testing, protects intellectual property and controls a manufactured product participates much further up the value chain.

That is where greater opportunities for enterprise value, skilled employment and sustainable growth can emerge.

8              Women Entrepreneurs and the Manufacturing Value Chain

This has particular significance for women's economic empowerment.

Across Africa, women are strongly represented in cosmetics and personal care entrepreneurship. Yet participation at the micro-enterprise or informal trading level does not necessarily translate into ownership of higher-value manufacturing activities.

Research on African cosmetics value chains has identified substantial female ownership among MSMEs, while also highlighting technological capabilities, regulation and skills as barriers to greater participation in manufacturing.

The challenge is therefore not simply to encourage more women to become entrepreneurs.

It is to create pathways that enable women-owned and women-led businesses to move from informal or small-scale production towards technically sophisticated, compliant and scalable manufacturing businesses.

Programmes such as the Cotisyl commercialisation initiative can contribute to this transition by giving entrepreneurs practical exposure to formulation science, product testing, intellectual property, contract manufacturing, branding and commercialisation.

This is economic empowerment through capability building, not simply participation.

9              The Opportunity for South Africa's Cosmetics Sector

The wider market environment makes this particularly relevant.

South Africa's beauty and personal care market continues to grow, with recent market analysis highlighting strong consumer interest in ingredient-led formulations combining natural ingredients with scientifically validated actives.

This creates an interesting opportunity for South African innovation.

Our universities generate scientific knowledge. Our entrepreneurs understand local consumers. South Africa has biodiversity, manufacturing capability and one of Africa's most developed retail networks.

The opportunity lies in connecting these assets.

University IP should not remain in laboratories or patent portfolios. SMMEs should not remain confined to low-value activities because they cannot independently access formulation expertise, testing facilities, manufacturing networks or commercialisation skills.

Technology transfer can provide the bridge.

10         From 20 Products to Sustainable Enterprises

The immediate output of the programme is tangible: five SMMEs, each supported through the development of four products.

But the more important outcome could be what happens afterwards.

Each entrepreneur emerges from the process with more than a product. They gain practical experience of structured product development, working with scientific intellectual property, managing testing requirements, developing brands, interacting with manufacturers and preparing products for commercial markets.

Those capabilities can be applied repeatedly to subsequent products.

That is how enterprise development becomes sustainable.

The ultimate measure of success is therefore not simply whether 20 products are produced. It is whether the participating SMMEs develop the capability and confidence to launch their next 20 products, enter new retail channels, employ more people and build sustainable manufacturing businesses.

11         Turning Innovation into Economic Impact

At Maravion, we believe that commercialisation is successful when innovation moves beyond the laboratory and begins creating measurable economic and social value.

The Cotisyl programme demonstrates what this can look like in practice: university-developed technology combined with entrepreneurial capability, scientific validation, product development, manufacturing and commercialisation support.

It is also an example of a broader model for inclusive innovation.

By connecting South African science with SMMEs, and particularly by creating opportunities for women entrepreneurs to participate in higher-value manufacturing, we can build businesses that do more than sell products.

We can build intellectual property, manufacturing capability, skilled employment and stronger local value chains.

From university laboratory, through formulation and testing, to a branded product ready for the retail shelf, this is the commercialisation journey Maravion is helping to enable.

And ultimately, that is where innovation begins to create impact.